Eisai and Biogen announced that the UK Medicines and Healthcare products Regulatory Agency has approved a once-every-four-weeks IV maintenance dosing regimen for Leqembi (lecanemab), an anti-amyloid monoclonal antibody for Alzheimer’s disease. The treatment was previously approved in August 2024 for adults with mild cognitive impairment or mild Alzheimer’s dementia who are ApoE ε4 heterozygotes or non-carriers.
Following 18 months of biweekly dosing at 10 mg/kg, patients may now either continue the same regimen or transition to monthly maintenance dosing. Leqembi targets both amyloid plaque and toxic protofibrils, addressing key drivers of neurodegeneration.
Because Alzheimer’s biomarkers can return once therapy stops, ongoing maintenance treatment is considered essential to sustaining benefits. The UK has an estimated 982,000 people living with dementia, most of whom have Alzheimer’s disease. Eisai leads global development and regulatory activities for lecanemab, with both companies co-commercializing the drug.